Free Trial

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

Acrivon Therapeutics logo
$1.11 +0.01 (+0.91%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Key Stats

Today's Range
$1.09
$1.14
50-Day Range
$1.10
$5.39
52-Week Range
$1.06
$10.16
Volume
87,305 shs
Average Volume
232,256 shs
Market Capitalization
$34.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.71
Consensus Rating
Buy

Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

ACRV MarketRank™: 

Acrivon Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 293rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Acrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Acrivon Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Acrivon Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Acrivon Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Acrivon Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Acrivon Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Acrivon Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.05% of the float of Acrivon Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Acrivon Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acrivon Therapeutics has recently decreased by 3.60%, indicating that investor sentiment is improving.
  • Dividend Yield

    Acrivon Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Acrivon Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.05% of the float of Acrivon Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Acrivon Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Acrivon Therapeutics has recently decreased by 3.60%, indicating that investor sentiment is improving.
  • News Sentiment

    Acrivon Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    6 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,009,858.00 in company stock.

  • Percentage Held by Insiders

    11.90% of the stock of Acrivon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Acrivon Therapeutics' insider trading history.
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
HC Wainwright Issues Optimistic Estimate for ACRV Earnings
See More Headlines

ACRV Stock Analysis - Frequently Asked Questions

Acrivon Therapeutics' stock was trading at $6.02 at the beginning of 2025. Since then, ACRV shares have decreased by 81.7% and is now trading at $1.10.
View the best growth stocks for 2025 here
.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.06.

Acrivon Therapeutics (ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Top institutional investors of Acrivon Therapeutics include Goldman Sachs Group Inc. (0.18%), Wealthedge Investment Advisors LLC (0.18%), Invesco Ltd. (0.11%) and Baker BROS. Advisors LP (0.07%). Insiders that own company stock include Ra Capital Management, LP, Ltd Chione and Perceptive Advisors Llc.
View institutional ownership trends
.

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

Last Earnings
5/13/2025
Today
5/30/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.71
High Stock Price Target
$30.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,510.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.39 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.38 per share
Price / Book
0.20

Miscellaneous

Free Float
28,489,000
Market Cap
$34.49 million
Optionable
Not Optionable
Beta
1.88
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ACRV) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners